for seven patients, and melphalan 200 mg/M2 intravenously alone for four. The median number of granulocytemacrophage colony forming units in the reinfused PBSC was 3*42X 104/kg (3-03-18-01 ) and bone marrow 12-4X104/ kg (4 16-28-6) . Neutrophil recovery to B0S5XI09/1 and platelet transfusion independence occurred at a median of 14 days (11) (12) (13) (14) (15) (16) (17) (18) and 22 days After myelosuppressive chemotherapy there is a massive increase in circulating progenitor cell levels.7 The accurate timing of PBSC collections with this surge improves progenitor cell yields.8-10 An alternative method of priming for PBSC collection involves use of the marrow growth factors granulocyte colony stimulating factor (G-CSF) or granulocytemacrophage colony stimulating factor (GM-CSF)."
A major factor in the toxicity of high dose treatment with autologous bone marrow transplantation (ABMT) is the period of myelosuppression, particularly in heavily pretreated patients. In order to achieve sustained engraftment after PBSC transplantation a number of PBSC harvest procedures may be required. A study in adults suggested that by combining PBSC transplantation and ABMT the number of leukaphereses could be reduced and a benefit from rapid, if transient, engraftment, was demonstrated.12 Eventual permanent engraftment was achieved later by the ABMT, but the combination reduced early morbidity.
With the aim of reducing the duration of neutropenia and thrombocytopenia, PBSC were similarly used in the current study to augment bone marrow rescue in a group of heavily pretreated patients. PBSC collections were timed to coincide with the surge of progenitor cells after routine chemotherapy. As the PBSC transplant was not intended to replace ABMT only two collections were planned without using marrow growth factors in order to minimise disruption of the regular chemotherapy schedule.
Patients and methods

PATIENTS AND HIGH DOSE CHEMOTHERAPY REGIMENS
Eleven patients aged 7-17 years received combined PBSC transplantation and ABMT (table 1) . There were five patients with Ewing's sarcoma, three with rhabdomyosarcoma, and one patient each with T cell lymphoma, acute myeloid leukaemia, and angiosarcoma of the liver. High dose treatment was used as consolidation of chemotherapy induced remission except for one patient with T cell lymphoma who was treated in relapse.
Mitchell, Shepherd, Proctor, Dainton, Cabral, Pinkerton Patients were isolated in filtered air rooms, although parents had free access. No particular procedures were followed regarding food and no gut sterilisation was used. Antifungal prophylaxis comprised oral amphotericin and nystatin, or fluconazole. All patients had a Hickman line with at least two lumens.
Pneumocystis prophylaxis was commenced at neutrophil recovery, with co-trimoxazole then being continued for six months.
Patients were transfused to maintain haemoglobin >90 g/l and platelets >20X 109/1. Cytomegalovirus IgG negative patients received only cytomegalovirus negative blood products, and all blood products were irradiated. BONE Neutrophil recovery was well sustained in four patients (cases 2, 6, 9, 11), while for two patients there was a minor dip in neutrophil levels (cases 1, 4). However, the other five patients showed only transient early engraftment, with neutrophils dropping again at day 16-19 below 0 *5 X 109/1 (figure).
One patient (case 5) with neutrophil recovery to 0-6X109/l at day 14, dropped to Peripheral blood stem cells used to augment autologous bone marrow transplantation some cases.3 In the current study there was no clear relationship between the stability of the early neutrophil rise and the infused PBSC CFU-GM count, although four out of five patients with unstable early engraftment received 3-3-5x104/kg CFU-GM. None of these patients had a history of bone marrow involvement by tumour, which is known to be associated with slow engraftment. Likewise there was no clear association between the duration of chemotherapy before leukapheresis and the stability of PBSC engraftment.
Early platelet engraftment has been the major advantage of PBSC reinfusion in adults. However, in several studies patients were less heavily pretreated than these children, a factor likely to influence platelet engraftment in particular. PBSC collections were carried out during the rebound after chemotherapy without the use of growth factors. The use of colony stimulating factors before collection has now been shown to improve progenitor cell yields,"I and our current practice is to utilise PBSC obtained by combined chemotherapy and G-CSF priming for four days before and during harvest. The use of marrow growth factors add significantly to the cost of the procedure and this study demonstrates that even without their use there is potential benefit.
The degree of cytoreduction achievable with a single course of high dose treatment is limited. Although in haematopoietic malignancies this may be curative this is less likely in solid tumours. In adults PBSC reinfusion allows repeated sequential high dose treatment,'3 a strategy that is feasible in the paediatric setting and could improve the poor prognosis of some paediatric tumours.
The precise advantages of PBSC reinfusion over ABMT in children have yet to be clarified. In the young child there may be little to choose between a general anaesthetic for marrow harvest and several hours on a cell separator. Randomised studies evaluating engraftment timing and procedure costs are needed. In patients with active marrow disease there is likely to be little advantage to PBSC rescue compared with ABMT. High dose treatment will be ineffective in either case and failure is due to chemoresistant disease in the child, not contamination of the reinfused marrow.
